El interés en corto de GeneDx Holdings da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de GeneDx Holdings. Los datos de interés en corto se actualizan cada dos semanas.

GeneDx Holdings (NASDAQ:WGS) Bolsa, Informe de interés en corto

GeneDx Holdings

GeneDx Hldgs

GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

LFCR

SPSC

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este viernes: WGS, LFCR, SPSC, RGP y UDR.

5 acciones en el foco este viernes: WGS, LFCR, SPSC, RGP y UDR

GeneDx Holdings Corp. - Class A Common Stock

GeneDx Holdings Corp

<a href="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20250512-1478052/1478052_dfs5.pdf" title="https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20250512-1478052/1478052_dfs5.pdf">https://www.spglobal.com/spdji/en/documents/indexnews/announcements/20250512-1478052/1478052_dfs5.pdf</a>

COIN

Coinbase Global Will Replace Discover Financial Services In The S&P 500 Effective Prior To The Opening Of Trading On Monday, May 19

Barclays analyst Lauren Lieberman maintains Kenvue (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>) with a Equal-Weight and raises the price target from $22 to $23.

Price Target

Analyst Ratings

KVUE

Barclays Maintains Equal-Weight on Kenvue, Raises Price Target to $23

Offerings

LQR House Files For Common Stock Offering Of Up To $25M

Barclays analyst Theresa Chen maintains HF Sinclair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DINO#NYSE">DINO</a>) with a Equal-Weight and raises the price target from $29 to $32.

DINO

Barclays Maintains Equal-Weight on HF Sinclair, Raises Price Target to $32

Life360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIF#NASDAQ">LIF</a>) affirms FY2025 sales outlook from $450.00 million-$480.00 million to $450.00 million-$480.00 million vs $466.67 million estimate.

Guidance

Life360 Affirms FY2025 Sales Guidance of $450.00M-$480.00M vs $466.67M Est

Lument Finance Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LFT#NYSE">LFT</a>) reported quarterly earnings of $0.08 per share which missed the analyst consensus estimate of $0.09 by 11.11 percent. This is a 20 percent decrease over earnings of $0.10 per share from the same period last year. The company reported quarterly sales of $7.74 million which missed the analyst consensus estimate of $9.51 million by 18.66 percent. This is a 40.47 percent decrease over sales of $12.99 million the same period last year.

Earnings Misses

CORRECTION: Lument Finance Trust Q1 Adj. EPS $0.08 Misses $0.09 Estimate, Sales $7.74M Miss $9.51M Estimate

MicroVision Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVIS#NASDAQ">MVIS</a>) reported first-quarter financial results after the market close on Monday. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/05/ac45359368/microvision-announces-first-quarter-2025-results">of the report</a>.
<ul class="wp-block-list">
<li>Q1 Revenue: $589,000, versus <a href="http://benzinga.com/quote/mvis/earnings">estimates</a> of $2.25 million</li>
</ul>
<ul class="wp-block-list">
<li>Q1 Adjusted Loss: 10 cents, versus estimates of seven cents</li>
</ul>
Total operating expenses were down 47% year-over-year to $14.1 million. The company ended the period with $69 million in cash, cash equivalents and investment securities. MicroVision noted that it also has access to $143.4 million of capital through its at-the-market facility and convertible note facility. 
&#8220;MicroVision is well-positioned to secure revenue opportunities for 2025 from the industrial vertical,&#8221; said Sumit Sharma, CEO of MicroVision. &#8220;Our unique value proposition continues to be our integrated perception software. We offer compelling solutions to industrial customers and automotive OEMs at attractive price points.&#8221;
MicroVision said its production commitment with ZF enables the company to commit to high-volume deliveries to fulfill demand in the range of $30 million to $50 million over the next 12 to 18 months. 
The company also highlighted the establishment of a defense industry advisory board in the quarter that aims to accelerate strategic expansion and pursuit of revenue opportunities in the defense tech and military sectors.
Executives are currently discussing the quarter on a conference call that kicked off at 4:30 p.m. ET. The company also plans to hold an Investor Day on May 20. 
MVIS Price Action: <a href="http://benzinga.com/quote/mvis">MicroVision shares</a> were down 15.72% after-hours at 83 cents at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45361467/archer-aviation-reports-smaller-than-expected-loss-in-q1-company-says-uae-launch-remains-on-track-for-2025-shares-surge">Archer Aviation Reports Smaller-Than-Expected Loss In Q1, Company Says UAE Launch Remains &#8216;On Track&#8217; For 2025, Shares Surge</a></li>
</ul>
Photo: courtesy of MicroVision.

Movers

MVIS

MicroVision Stock Tumbles On Q1 Earnings Miss, Company Highlights Industrial Revenue Opportunities, Targets Defense Tech, Military Expansion

CTRI

Centuri Holdings Files For Mixed Shelf Of Up To $500M

ClearPoint Neuro, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLPT#NASDAQ">CLPT</a>) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it has entered into a note financing arrangement with Oberland Capital Management LLC ("Oberland Capital") of up to $105 Million, with $30.0 million of gross proceeds funded at closing. Additional note financing will be provided to the Company by Oberland Capital under the following terms:
An additional $25.0 million at the option of the Company any time prior to December 31, 2026; and
An additional $50.0 million at the option of the Company and Oberland Capital any time prior to December 31, 2026.
In addition to the note financing, the Company entered into a stock purchase agreement with Oberland Capital whereby Oberland Capital purchased 275,808 shares of the Company's common stock at a price of $12.69 per share in a registered direct offering, representing an additional $3,500,003.52 of gross proceeds to the Company. The price per share was equal to the trailing 30-trading days volume-weighted average price for the period ending on the day prior to the date of the stock purchase agreement. Oberland Capital also has the right to participate in a future offering of the Company's common stock in an amount of $1.5 million on or before December 31, 2026.

CLPT

ClearPoint Neuro Secures Up To $105M In Note Financing From Oberland Capital With $30M Funded At Closing, Gains Additional $3.5M Through Direct Stock Sale At $12.69/Share, And Retains Option For $75M More Plus Future $1.5M Equity Participation Through 2026

Barclays analyst Julian Mitchell maintains Regal Rexnord (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRX#NYSE">RRX</a>) with a Overweight and raises the price target from $155 to $160.

Barclays Maintains Overweight on Regal Rexnord, Raises Price Target to $160

Village Farms Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.01) by 500 percent. This is a 100 percent decrease over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $77.07 million which beat the analyst consensus estimate of $76.28 million by 1.04 percent. This is a 1.28 percent decrease over sales of $78.08 million the same period last year.

Earnings Beats

Village Farms Intl Q1 EPS $(0.06) Misses $(0.01) Estimate, Sales $77.07M Beat $76.28M Estimate

<a href="https://www.bloomberg.com/news/articles/2025-05-12/amc-to-slash-movie-ticket-prices-by-50-on-wednesdays?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-05-12/amc-to-slash-movie-ticket-prices-by-50-on-wednesdays?embedded-checkout=true</a>

General

'AMC to Slash Movie Ticket Prices by 50% on Wednesdays'- Bloomberg

Barclays analyst Julian Mitchell maintains Kennametal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMT#NYSE">KMT</a>) with a Equal-Weight and raises the price target from $22 to $24.

Barclays Maintains Equal-Weight on Kennametal, Raises Price Target to $24

BSLK

Bolt Projects Holdings Sees FY2026 Revenue To Be At Least $9M

Microvast Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) affirms FY2025 sales outlook from $450.00 million-$475.00 million to $450.00 million-$475.00 million vs $462.97 million estimate.

MVST

Microvast Holdings Affirms FY2025 Sales Guidance of $450.00M-$475.00M vs $462.97M Est

Bolt Projects Holdings Sees FY2025 Revenue Of Atleast $4.5M

Copart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRT#NASDAQ">CPRT</a>) has outperformed the market over the past 15 years by 12.98% on an annualized basis producing an average annual return of 24.58%. Currently, Copart has a market capitalization of $60.14 billion. 
Buying $100 In CPRT: If an investor had bought $100 of CPRT stock 15 years ago, it would be worth $2,674.99 today based on a price of $62.25 for CPRT at the time of writing.
<h3>Copart's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747084514_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CPRT

If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today

Village Farms International Announces Transformative Transaction to Privatize Its Fresh Produce Business; Village Farms' Fresh Segment To Become Cornerstone Of Newco's Commercial Operations And Growth Strategy; Expects To Receive $40M In Cash Proceeds; 37.9% Equity Ownership Interest In Newco; Retains Ownership Of All Canadian Cultivation Assets

Bolt Projects Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSLK#NASDAQ">BSLK</a>) reported quarterly losses of $(3.00) per share. This is a 89.37 percent increase over losses of $(28.22) per share from the same period last year. The company reported $171.00 thousand in sales this quarter. This is a 800.00 percent increase over sales of $19.00 thousand the same period last year.

Bolt Projects Holdings Q1 EPS $(3.00) Up From $(28.22) YoY, Sales $171.00K Up From $19.00K YoY

Central Puerto (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CEPU#NYSE">CEPU</a>) reported quarterly earnings of $0.50 per share. This is a 150 percent increase over earnings of $0.20 per share from the same period last year. The company reported $196.00 million in sales this quarter. This is a 130.67M percent increase over sales of $150.00 the same period last year.

CEPU

Central Puerto Q1 EPS $0.50 Up From $0.20 YoY, Sales $196.00M Up From $150.00 YoY

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS

GeneDx to Showcase Key Research and Innovation at the 2025 American College of Medical Genetics (ACMG) Annual Meeting

GeneDx Enhances the Power of its Interpretation Platform with Artificial Intelligence (AI) Powered Gene Ranker to Enable Faster and More Efficient Clinical Analysis

Fast Company Recognizes GeneDx as One of the World's Most Innovative Companies

GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GeneDx Expands Commercial Footprint for Exome and Genome Testing with Inborn Errors of Immunity as a New Indication

GeneDx to Report First Quarter 2025 Financial Results on Wednesday, April 30, 2025

GeneDx to Acquire Fabric Genomics, Enabling Decentralized, AI-Powered Testing at Global Scale

GeneDx Reports First Quarter 2025 Financial Results and Business Highlights

GeneDx Announces Completion of Fabric Genomics Acquisition

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Agilon Health

Amedisys

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna Group

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

GeneDx Holdings

Interés en corto

GeneDx Holdings (NASDAQ:WGS) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL